title: Osteonecrosis of the jaw.
abstract: This review looks at osteonecrosis in the stomatognathic system (mainly the jaws). Osteonecrosis of the jaw (ONJ) is a rare but serious clinical condition. It affects patients treated with bisphosphonates, and also with denosumab, mainly in oncological doses. In osteoporosis, it is a problem of relatively small significance. Article presents a thorough review of this phenomenon, including its definition, pathogenesis, risk factors, prevention and treatment methods, and its incidence rate.
authors.affiliation: Chair and Department of Pathomorphology, Zabrze, Medical University of Silesia, Katowice, Poland. bognadr@poczta.onet.pl
authors.forename: Bogna
authors.initials: B
authors.lastname: Drozdzowska
mesh_terms: D019386:Alendronate / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D000069448:Denosumab; D004164:Diphosphonates / Q000009:adverse effects; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced* / Q000517:prevention & control*; D010020:Osteonecrosis / Q000139:chemically induced* / Q000517:prevention & control*; D053245:RANK Ligand / Q000009:adverse effects; D012307:Risk Factors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D053245:RANK Ligand; D000069448:Denosumab; D019386:Alendronate